Nachrichten zur Pfizer Inc. Aktie

PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?

Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength…

Pfizer Buy

NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Pfizer nach einem Treffen mit dem Management am…

Jefferies belässt Pfizer auf Buy - Ziel 34 Dollar

NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Pfizer nach einem Treffen mit dem Management am…

ANALYSE-FLASH: JPMorgan belässt Pfizer auf 'Neutral' - Ziel 30 Dollar

NEW YORK (dpa-AFX) - Die US-Bank JPMorgan hat die Einstufung für Pfizer nach starken EV-303-Studiendaten…

ANALYSE-FLASH: JPMorgan belässt Pfizer auf Neutral - Ziel 30 Dollar

NEW YORK (dpa-AFX) - Die US-Bank JPMorgan hat die Einstufung für Pfizer nach starken EV-303-Studiendaten mit einem Kursziel von…

Pfizer: World-Leading Drug Pipeline Sets Stage For Major Long-Term Potential

…

Pfizer (PFE) Beats Stock Market Upswing: What Investors Need to Know

Pfizer (PFE) concluded the recent trading session at $24.51, signifying a +1.16% move from its prior days close.…

What Pfizer And AstraZeneca’s Deals With The Trump Administration Mean For Pharma

With the administration’s aggressive tactics, pharmaceutical companies cannot avoid this reckoning, but they can shape how it unfolds.…

QSM Asset Management Takes $11.5 Million Stake in Rio Tinto, Expands Energy Exposure

Key PointsLondon-based QSM Asset Management acquired 174,700 shares of Rio Tinto Group for an estimated $11.5 million in the third…

QSM Asset Management Buys $6.8 Million of Pfizer Stock as Pharma Giant Lags Market

Key PointsQSM Asset Management added 276,899 shares of Pfizer for an estimated $6.8 million in the third quarter.The transaction value…

CEOs of Wells Fargo and Pfizer caution the U.S. could lose its edge to China without innovation

Speaking at CNBCs Invest in America Forum, the CEOs said the U.S. still leads in many sectors, but inconsistent policy…

Pfizer CEO says US pharma industry needs to collaborate with China

Pfizer Chief Executive Albert Bourla said on Tuesday that the U.S. pharmaceutical industry needs to collaborate with China’s, where speedy…

Where Will Pfizer Be in 5 Years? @themotleyfool #stocks $PFE $MTSR

Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should…

AstraZeneca agrees to offer US discounts in exchange for no tariffs

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has become the second giant drugmaker to announce a drug pricing deal with the US government, after Pfizers…

4 Dividend Stocks to Double Up on Right Now -- Including United Parcel Service and Pfizer

These great dividend stocks merit more attention from income investors.…

Preisdruck bei Medikamenten: Welcher Pharmariese schluckt Trumps bittere Pille als Nächstes?

Nach einem ersten erfolglosen Anlauf erzielt US-Präsident Trump einen Sieg im Kampf gegen teure Medikamente. Pfizer senkt seine Preise und…

Trump reaches deal with AstraZeneca to lower U.S. drug prices, MSNBC reports

Trump is set to announce the agreement with AstraZeneca on Friday, after striking a similar deal with Pfizer late last…

Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly

Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after…

Heres Why Pfizer (PFE) Fell More Than Broader Market

In the latest trading session, Pfizer (PFE) closed at $25.24, marking a -1.71% move from the previous day.…

Pfizer: Mastering The Art Of The Deal With Metsera - Upgraded To Buy

…

Down 50%, Should You Buy the Dip on Pfizer? @themotleyfool #stocks $PFE $MTSR

Pfizers stock price is down materially from its 2021 highs, but it is also up notably from its April 2025…

Down 50%, Should You Buy the Dip on Pfizer?

Pfizers stock price is down materially from its 2021 highs, but it is also up notably from its April 2025…

Life sciences sentiment rises as Pfizer deal eases tariff concerns

Sentiment towards life sciences tools and diagnostics firms in North America is turning positive after an agreement between the Trump…

Pro traders are watching Pfizer after a big move last week and two other stocks with earnings on deck

Jay Woods, chief market strategist at Freedom Capital Markets, highlighted a few beaten-down names that could become strong buying opportunities.…

Eli Lilly Stock Rises 16% in a Week: Heres What You Should Know

LLY shares have jumped 16% last week as Pfizers landmark government deal boosted investor confidence across the pharma sector.…

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for…

AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?

ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizers landmark drug-pricing deal with the Trump…

Pfizer Aktienanalyse: Trump-Deal bringt Kursfantasie - BofA hebt Kursziel auf 30 USD an

Bad Marienberg (www.aktiencheck.de)???? Kursfantasie bleibt begrenzt - Analyst Tim Anderson sieht Pfizer weiterhin im Bewertungs-MittelfeldDie US-Investmentbank BofA hat am 03.…

Trump’s Drug Price Initiative Has No Impact On Typical U.S. Patients’ Costs

Trump touted a deal with Pfizer in which the firm will sell drugs at discounts on a website called TrumpRx.…

Can Pfizers Stock Break This Disappointing Streak? @themotleyfool #stocks $PFE

Pfizers stock has been struggling for multiple years, and even a low valuation hasnt made it an enticing option for…

Pfizer – TrumpRx deal boosts Big Pharma to a record rally

…

Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know

Pfizer (PFE) closed at $27.37 in the latest trading session, marking a +1.07% move from the prior day.…

Why Shares of Eli Lilly Soared This Week

Pfizers deal with the Trump administration raised hopes that Eli Lilly would also avoid pharmaceutical tariffs.…

MRK Stock Up Nearly 14% So Far This Week: Whats Driving It?

Merck shares climb nearly 14% as Pfizers landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma…

Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump?

Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.…

Pfizer Just Made a Landmark Drug Pricing Agreement with President Donald Trump. Is the Stock a Buy? @themotleyfool #stocks $PFE

The pharma giant just eliminated two big risks.…

dpa-AFX ProFeed